These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 15528975)
1. Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression. Medina-Gundrum L; Cerna C; Gomez L; Izbicka E Invest New Drugs; 2005 Jan; 23(1):3-9. PubMed ID: 15528975 [TBL] [Abstract][Full Text] [Related]
2. AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients. Medina-Gundrum L; Cerna C; Gomez LR; Yochmowitz M; Weitman S Anticancer Drugs; 2003 Apr; 14(4):275-80. PubMed ID: 12679731 [TBL] [Abstract][Full Text] [Related]
3. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y. Tanaka H; Ohshima N; Ikenoya M; Komori K; Katoh F; Hidaka H Cancer Res; 2003 Oct; 63(20):6942-7. PubMed ID: 14583495 [TBL] [Abstract][Full Text] [Related]
4. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro. Eckardt JR; Burris HA; Kuhn JG; Bissery MC; Klink-Alakl M; Clark GM; Von Hoff DD J Natl Cancer Inst; 1994 Jan; 86(1):30-3. PubMed ID: 8271279 [TBL] [Abstract][Full Text] [Related]
5. Activity of oxaliplatin against human tumor colony-forming units. Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898 [TBL] [Abstract][Full Text] [Related]
6. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Petit T; Izbicka E; Lawrence RA; Bishop WR; Weitman S; Von Hoff DD Ann Oncol; 1999 Apr; 10(4):449-53. PubMed ID: 10370788 [TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Takagi M; Honmura T; Watanabe S; Yamaguchi R; Nogawa M; Nishimura I; Katoh F; Matsuda M; Hidaka H Invest New Drugs; 2003 Nov; 21(4):387-99. PubMed ID: 14586206 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units. Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294 [TBL] [Abstract][Full Text] [Related]
9. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485 [TBL] [Abstract][Full Text] [Related]
10. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Garland LL; Taylor C; Pilkington DL; Cohen JL; Von Hoff DD Clin Cancer Res; 2006 Sep; 12(17):5182-9. PubMed ID: 16951237 [TBL] [Abstract][Full Text] [Related]
11. Activity of temozolomide against human tumor colony-forming units. Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562 [TBL] [Abstract][Full Text] [Related]
12. Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units. Cobb PW; Degen DR; Clark GM; Chen SF; Kuhn JG; Gross JL; Kirshenbaum MR; Sun JH; Burris HA; Von Hoff DD J Natl Cancer Inst; 1994 Oct; 86(19):1462-5. PubMed ID: 8089865 [TBL] [Abstract][Full Text] [Related]
13. Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units. Petit T; Izbicka E; Lawrence RA; Nalin C; Weitman SD; Von Hoff DD Anticancer Drugs; 1999 Mar; 10(3):309-15. PubMed ID: 10327038 [TBL] [Abstract][Full Text] [Related]
15. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27. Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627 [TBL] [Abstract][Full Text] [Related]
16. A gene expression database for the molecular pharmacology of cancer. Scherf U; Ross DT; Waltham M; Smith LH; Lee JK; Tanabe L; Kohn KW; Reinhold WC; Myers TG; Andrews DT; Scudiero DA; Eisen MB; Sausville EA; Pommier Y; Botstein D; Brown PO; Weinstein JN Nat Genet; 2000 Mar; 24(3):236-44. PubMed ID: 10700175 [TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Györffy B; Surowiak P; Kiesslich O; Denkert C; Schäfer R; Dietel M; Lage H Int J Cancer; 2006 Apr; 118(7):1699-712. PubMed ID: 16217747 [TBL] [Abstract][Full Text] [Related]
18. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539 [TBL] [Abstract][Full Text] [Related]
19. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Britten CD; Izbicka E; Hilsenbeck S; Lawrence R; Davidson K; Cerna C; Gomez L; Rowinsky EK; Weitman S; Von Hoff DD Cancer Chemother Pharmacol; 1999; 44(2):105-10. PubMed ID: 10412943 [TBL] [Abstract][Full Text] [Related]
20. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Siu LL; Von Hoff DD; Rephaeli A; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Eckhardt SG Invest New Drugs; 1998; 16(2):113-9. PubMed ID: 9848574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]